Adjunctive fasting is the practice of fasting alongside a primary medical treatment, rather than as a standalone therapy. The word “adjunctive” simply means “added to,” so adjunctive fasting refers to periods of reduced or zero calorie intake timed around treatments like chemotherapy, diabetes medication, or anti-inflammatory therapies to potentially improve their effectiveness or reduce side effects.
How Adjunctive Fasting Differs From Regular Fasting
Regular fasting, whether for weight loss or general health, is typically done on its own. Adjunctive fasting is specifically coordinated with another medical intervention. The fasting period is timed to begin before a treatment and often extends afterward, with the goal of putting the body into a metabolic state that makes the primary therapy work better.
In cancer care, for example, patients may fast for 24 to 72 hours before a chemotherapy session and continue fasting for up to 24 hours after. Clinical protocols have varied: some involve complete water-only fasts for 48 hours surrounding a chemo cycle, while others use a modified approach that allows 400 to 600 calories per day from a ketogenic diet for 72 hours before and 24 hours after treatment. These aren’t arbitrary windows. They’re designed to shift the body’s metabolism away from growth mode and into a protective, stress-resistant state before the treatment hits.
The Biology Behind It
The core idea driving adjunctive fasting in cancer treatment is a concept called differential stress resistance. When you fast, your healthy cells respond to the drop in nutrients and growth signals by essentially going into a defensive posture. They slow down growth and activate internal protective mechanisms, making them more resilient to damage from things like chemotherapy drugs.
Cancer cells can’t do this. Because they’re driven by permanently “on” growth signals (oncogenes), they can’t switch into that same protective mode. Fasting may actually make them more vulnerable, increasing the production of damaging molecules inside the tumor cells while your normal cells hunker down. Researchers have called this flip side “differential stress sensitization,” where cancer cells become easier to kill at the same time healthy cells become harder to damage.
Beyond cancer, fasting triggers a cellular cleanup process called autophagy, where cells break down and recycle damaged components. This housekeeping function kicks in during nutritional deprivation and is thought to contribute to the anti-inflammatory and regenerative effects seen in several adjunctive fasting applications.
Adjunctive Fasting in Cancer Treatment
The strongest theoretical case for adjunctive fasting exists in oncology, where it has been studied alongside chemotherapy, radiotherapy, immunotherapy, and targeted drug therapies. The goal is twofold: protect healthy tissue from treatment toxicity and potentially make tumors more responsive to the drugs.
The clinical reality, however, is more complicated than the theory suggests. A 2023 systematic review and meta-analysis pooling data from multiple trials found no significant difference in chemotherapy side effects between patients who fasted and those who ate normally. The pooled results showed fasting didn’t reduce the overall risk of adverse events, including neutropenia (a dangerous drop in white blood cells that’s one of chemo’s most common complications). The review did confirm that fasting periods of 24 to 72 hours around chemotherapy were well tolerated and didn’t cause serious harm, but the hoped-for reduction in toxicity hasn’t been proven in high-quality clinical data.
This doesn’t mean the approach is useless. It means the evidence is still catching up to the biology. Individual studies have reported improvements in quality of life and certain side effects, but when the data is combined and analyzed rigorously, clear benefits haven’t emerged yet.
Adjunctive Fasting for Type 2 Diabetes
In diabetes care, intermittent fasting used alongside standard medications has shown more consistent results. Multiple studies have demonstrated improvements in blood sugar control, insulin sensitivity, and body weight when fasting is added to a diabetes management plan.
The numbers are concrete. One study found that the body’s ability to take up sugar in response to insulin increased from 6.3 to 7.3 mg/min/kg after a period of intermittent fasting, even without significant weight loss. A systematic review of clinical trials showed that patients with metabolic syndrome who added intermittent fasting saw meaningful reductions in insulin resistance, with average insulin levels dropping by about 13 units.
Perhaps the most striking finding is how powerfully fasting can affect medication needs. In a 2023 study, patients with type 2 diabetes who were already on insulin reduced their doses significantly after just 12 weeks of intermittent fasting. Some studies have found that fasting can even eliminate the need for insulin supplementation entirely. Fasting lowers blood sugar so effectively that medication doses often need to be reduced to prevent dangerously low blood sugar episodes. This is precisely why adjunctive fasting for diabetes requires close medical supervision: the interaction between fasting and medication is real and potent, and getting the balance wrong can be harmful.
Adjunctive Fasting and Inflammation
Fasting has also been studied as an add-on approach for inflammatory and autoimmune conditions, particularly rheumatoid arthritis. The evidence here points to short-term improvements in disease activity, with measurable drops in key inflammatory markers.
One study found that a seven-day fasting intervention reduced interleukin-6, a major driver of inflammation, by 37%. That reduction correlated with lower C-reactive protein levels (a general marker of inflammation used to track disease activity) and improvements in clinical symptoms. Across multiple studies, patients experienced reduced joint swelling, pain, and stiffness alongside drops in inflammatory blood markers.
Part of the mechanism involves the gut. When you fast, the balance of bacteria in your intestines shifts, increasing production of short-chain fatty acids like butyrate and propionate. These compounds suppress inflammatory signaling pathways and reduce the production of proteins that drive autoimmune flares. The effect is real but tends to be short-lived. Most studies show that RA symptoms return once normal eating resumes, which is why fasting in this context works best as a recurring adjunct rather than a one-time intervention.
Fasting-Mimicking Diets as an Alternative
Not everyone can or should do a complete fast, especially around medical treatments. Fasting-mimicking diets were developed to trigger many of the same metabolic shifts while still allowing some food intake. These diets typically provide about 40% to 50% of normal calories on the first day, then drop to 10% to 20% for the following four days. The macronutrient balance is roughly 10% protein, 45% fat, and 45% carbohydrates.
The low protein content is intentional. Protein and amino acids are strong activators of growth-signaling pathways, so keeping protein minimal helps the body enter the same protective, low-growth state that a full fast would produce. These diets are used in clinical trials as a more practical and sustainable version of adjunctive fasting, particularly for cancer patients who may already be at risk of malnutrition.
Risks and Practical Limits
Adjunctive fasting is not appropriate for everyone. People who are underweight, malnourished, pregnant, or have a history of eating disorders are generally excluded from fasting protocols. For cancer patients already losing weight from their disease or treatment, adding calorie restriction can be counterproductive.
The interaction between fasting and medication is the most immediate practical concern. In diabetes, fasting without adjusting insulin or other blood-sugar-lowering drugs can cause hypoglycemia, which can be dangerous. In cancer care, fasting around chemotherapy needs to be timed carefully, and the protocols tested in clinical trials vary widely, from 48-hour water-only fasts to multi-day modified diets. There is no single standardized approach, which makes self-directed adjunctive fasting risky. The fasting periods used in research were supervised, with medication adjustments made in real time based on how patients responded.